Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IM 5-MeO-DMT in Healthy Subjects
NCT05698095Phase 1Completed
- Sponsor
- Usona Institute
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 5-MeO-DMT in major depressive disorder (MDD) (9 cohorts), sponsored by Usona Institute. Primary endpoint: Treatment Emergent Adverse Events at 30 days. Started Dec 2022; status: completed.
02
Drugs
5-MeO-DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05698095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698095.